Biopharma Can Live With Boris’s Brexit Deal – But Will It Pass?
Parliament Will Scrutinize Deal On Saturday
Executive Summary
Industry would settle for UK Prime Minister Boris Johnson’s deal, with sweeteners promised for the sector
You may also be interested in...
UK Signs First No-Deal Brexit Ferry Contracts
If the UK leaves the EU without a deal at the end of this month, pharmaceutical companies will be able to book space for medicine deliveries on ferries run by four operators between UK and EU ports.
Novartis Nominates Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.
Corbus And Janux Lead Q1’s Small-Cap Winners
Corbus has presence in both antibody drug conjugates and obesity, and was the stand-out small-cap target for investors with a fivefold increase in its share price in Q1.